205 related articles for article (PubMed ID: 16172856)
1. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
Samra Z; Yardeni M; Peled N; Bishara J
Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):592-5. PubMed ID: 16172856
[TBL] [Abstract][Full Text] [Related]
2. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.
Pfaller MA; Jones RN; Doern GV; Sader HS; Hollis RJ; Messer SA
J Clin Microbiol; 1998 Jul; 36(7):1886-9. PubMed ID: 9650930
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Marco F; Pfaller MA; Messer S; Jones RN
Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
[TBL] [Abstract][Full Text] [Related]
4. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
Pfaller MA; Diekema DJ; Jones RN; Sader HS; Fluit AC; Hollis RJ; Messer SA;
J Clin Microbiol; 2001 Sep; 39(9):3254-9. PubMed ID: 11526159
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents.
Arias A; Arévalo MP; Andreu A; Rodríguez C; Sierra A
Mycoses; 1994; 37(7-8):285-9. PubMed ID: 7739661
[TBL] [Abstract][Full Text] [Related]
6. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients.
Wong-Beringera A; Hindler J; Brankovic L; Muehlbauer L; Steele-Moore L
Diagn Microbiol Infect Dis; 2001 Jan; 39(1):25-31. PubMed ID: 11173188
[TBL] [Abstract][Full Text] [Related]
7. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ
J Clin Microbiol; 2003 Apr; 41(4):1440-6. PubMed ID: 12682127
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada.
St-Germain G; Laverdière M; Pelletier R; Bourgault AM; Libman M; Lemieux C; Noël G
J Clin Microbiol; 2001 Mar; 39(3):949-53. PubMed ID: 11230409
[TBL] [Abstract][Full Text] [Related]
9. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States.
Pfaller MA; Messer SA; Hollis RJ; Jones RN; Doern GV; Brandt ME; Hajjeh RA
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):217-22. PubMed ID: 10212747
[TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
Kovacicova G; Krupova Y; Lovaszova M; Roidova A; Trupl J; Liskova A; Hanzen J; Milosovic P; Lamosova M; Macekova L; Szovenyiova Z; Purgelova A; Obertik T; Bille J; Krcmery V
J Infect Chemother; 2000 Dec; 6(4):216-21. PubMed ID: 11810569
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
Pfaller MA; Messer SA; Hollis RJ; Jones RN; Doern GV; Brandt ME; Hajjeh RA
Antimicrob Agents Chemother; 1998 Dec; 42(12):3242-4. PubMed ID: 9835520
[TBL] [Abstract][Full Text] [Related]
12. Antifungal susceptibility of Candida isolates at the American University of Beirut Medical Center.
Araj GF; Daher NK; Tabbarah ZA
Int J Antimicrob Agents; 1998 Nov; 10(4):291-6. PubMed ID: 9916903
[TBL] [Abstract][Full Text] [Related]
13. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).
Safdar A; Chaturvedi V; Koll BS; Larone DH; Perlin DS; Armstrong D
Antimicrob Agents Chemother; 2002 Oct; 46(10):3268-72. PubMed ID: 12234857
[TBL] [Abstract][Full Text] [Related]
14. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.
Kronvall G; Karlsson I
J Clin Microbiol; 2001 Apr; 39(4):1422-8. PubMed ID: 11283066
[TBL] [Abstract][Full Text] [Related]
15. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).
Pfaller MA; Jones RN; Doern GV; Fluit AC; Verhoef J; Sader HS; Messer SA; Houston A; Coffman S; Hollis RJ
Diagn Microbiol Infect Dis; 1999 Sep; 35(1):19-25. PubMed ID: 10529877
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Monzón A; Rodríguez-Tudela JL
Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):432-5. PubMed ID: 10442422
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
Nguyen MH; Yu CY
J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
[TBL] [Abstract][Full Text] [Related]
20. Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.
Cuenca-Estrella M; Gomez-Lopez A; Cuesta I; Zaragoza O; Mellado E; Rodriguez-Tudela JL;
Antimicrob Agents Chemother; 2011 Apr; 55(4):1794-7. PubMed ID: 21282420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
